From DCAT Value Chain Insights (VCI)
Anacor Pharmaceuticals, Inc. has named Graeme Bell as executive vice president and chief financial officer, effective June 1, 2015. Mr. Bell has more than 20 years of global financial experience in the pharmaceutical industry and will succeed Geoffrey M. Parker, who willl remain with Anacor as a consultant to support the transition.
Mr. Bell joins Anacor from Merck & Co., Inc., where he served since 2010 as its vice president, country CFO, US, Human Health, responsible for the financial oversight and support of Merck's US pharmaceutical and vaccine business. Prior to his most recent role, Mr. Bell served in a number of positions of increasing responsibility at Merck, including as its Global Pharmaceutical Franchises Controller from 2009 to 2010, Country CFO, UK from 2008 to 2009 and Global Head of Investor Relations from 2004 to 2008.
Source: Anacor Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription